PP11 LEVELS OF CARCINOEMBRYONIC ANTIGEN (CEA) AND CLUSTER OF DIFFERENTIATION 4 (CD4+) IN NON-SMALL CELL LUNG CANCER PATIENTS

Andry Elisa Beruat1, Setia Putra Tariganr2, Noni N. Soeroso2
Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia1
Division of Pulmonary Oncology, Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Sumatera Utara2

Background:

Carcinoembryogenic antigen (CEA) is one of the tumor markers for non-small cell lung cancer (NSCLC) that can be used as a prognostic marker, predictor of efficacy for chemotherapy, and marker of postoperative recurrence and metastasis. Cluster Of Differentiation 4 (CD4+) are responsible for priming and expanding tumor-specific CD8. It plays a complicated role in lung cancer, coordinating immune responses, and impacting prognosis and metastatic risk.

Objective:

The objective of this study is measuring levels of CEA and CD4+ in NSCLC patients.

Methods:

This study is a cross-sectional study using patient blood collection with the Elisa method to see the levels of CEA and CD4+ in patients with NSCLC in Medan City. The result was analyzed using a statistical program (SPSS).

Results:

Most NSCLC patients were male, with as many as 20 patients (100%), 14 cases (70%) from Stage IVA as the stage majority of NSCLC. Based on the type of histology, most NSCLC patients had adenocarcinoma-type lung cancer, with as many as 12 (60%), 7 (35%) squamous cell carcinoma-type lung cancer, and only 1 (5%) large cell carcinoma-type lung cancer. CEA levels of NSCLC patients showed an increase of 3 samples (15%), while CD4+ increased in 1 sample (5%). The maximum CD4+ value was 32.523, with 0.5441 as the minimum. The mean level was 5.425. The maximum CEA value was 15.528, with 0.083 as the minimum. The mean level was (22.425).

Conclusion:

A combination of CEA and CD4+ can be used as prognostics and treatment predictors, in addition to being more affordable and easier to work with.